217 related articles for article (PubMed ID: 21670315)
1. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.
Kmieciak M; Basu D; Payne KK; Toor A; Yacoub A; Wang XY; Smith L; Bear HD; Manjili MH
J Immunol; 2011 Jul; 187(2):708-17. PubMed ID: 21670315
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.
Payne KK; Zoon CK; Wan W; Marlar K; Keim RC; Kenari MN; Kazim AL; Bear HD; Manjili MH
Breast Cancer Res Treat; 2013 Nov; 142(1):45-57. PubMed ID: 24197563
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.
Kmieciak M; Toor A; Graham L; Bear HD; Manjili MH
J Vis Exp; 2011 Jan; (47):. PubMed ID: 21304453
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.
Morales JK; Kmieciak M; Graham L; Feldmesser M; Bear HD; Manjili MH
Cancer Immunol Immunother; 2009 Jun; 58(6):941-53. PubMed ID: 18979098
[TBL] [Abstract][Full Text] [Related]
5. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
6. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.
Payne KK; Keim RC; Graham L; Idowu MO; Wan W; Wang XY; Toor AA; Bear HD; Manjili MH
J Leukoc Biol; 2016 Sep; 100(3):625-35. PubMed ID: 26928306
[TBL] [Abstract][Full Text] [Related]
7. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
8. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
10. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
11. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
Cha E; Graham L; Manjili MH; Bear HD
Breast Cancer Res Treat; 2010 Jul; 122(2):359-69. PubMed ID: 19826947
[TBL] [Abstract][Full Text] [Related]
12. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
Li H; Han Y; Guo Q; Zhang M; Cao X
J Immunol; 2009 Jan; 182(1):240-9. PubMed ID: 19109155
[TBL] [Abstract][Full Text] [Related]
13. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
14. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.
Helms MW; Prescher JA; Cao YA; Schaffert S; Contag CH
Cancer Immunol Immunother; 2010 Sep; 59(9):1325-34. PubMed ID: 20532883
[TBL] [Abstract][Full Text] [Related]
15. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
Aqbi HF; Coleman C; Zarei M; Manjili SH; Graham L; Koblinski J; Guo C; Xie Y; Guruli G; Bear HD; Idowu MO; Habibi M; Wang XY; Manjili MH
Breast Cancer Res; 2020 Oct; 22(1):116. PubMed ID: 33115528
[TBL] [Abstract][Full Text] [Related]
16. Mouse CD8
Li Z; Wu Y; Wang C; Zhang M
Cancer Immunol Immunother; 2019 Aug; 68(8):1303-1315. PubMed ID: 31278476
[TBL] [Abstract][Full Text] [Related]
17. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
18. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
19. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells.
Kitajima M; Ito T; Tumes DJ; Endo Y; Onodera A; Hashimoto K; Motohashi S; Yamashita M; Nishimura T; Ziegler SF; Nakayama T
Cancer Res; 2011 Jul; 71(14):4790-8. PubMed ID: 21646476
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
